117 related articles for article (PubMed ID: 30188400)
1. A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality.
Hall BR; Cannon A; Atri P; Wichman CS; Smith LM; Kumar S; Batra SK; Wang H; Ganti AK; Sasson AR; Are C
Ann Surg; 2020 Feb; 271(2):296-302. PubMed ID: 30188400
[TBL] [Abstract][Full Text] [Related]
2. Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis.
He C; Zhang Y; Cai Z; Lin X
BMC Cancer; 2019 May; 19(1):509. PubMed ID: 31142278
[TBL] [Abstract][Full Text] [Related]
3. Disparities in National Cancer Institute and Nonprofit Organization Funding Disproportionately Affect Cancers With Higher Incidence Among Black Patients and Higher Mortality Rates.
Kamath SD; Chen Y
JCO Oncol Pract; 2024 Mar; 20(3):378-385. PubMed ID: 38190584
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
5. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
6. Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores.
Spencer RJ; Rice LW; Ye C; Woo K; Uppal S
Gynecol Oncol; 2019 Jan; 152(1):106-111. PubMed ID: 30404721
[TBL] [Abstract][Full Text] [Related]
7. Marital status and survival in pancreatic cancer patients: a SEER based analysis.
Baine M; Sahak F; Lin C; Chakraborty S; Lyden E; Batra SK
PLoS One; 2011; 6(6):e21052. PubMed ID: 21698253
[TBL] [Abstract][Full Text] [Related]
8. County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Brooke BS; Stoddard GJ; Firpo MA; Scaife CL
Ann Surg; 2020 Dec; 272(6):1102-1109. PubMed ID: 30973391
[TBL] [Abstract][Full Text] [Related]
9. An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values.
Carter AJ; Delarosa B; Hur H
Health Res Policy Syst; 2015 Nov; 13():62. PubMed ID: 26526609
[TBL] [Abstract][Full Text] [Related]
10. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Amin S; Mhango G; Lin J; Aronson A; Wisnivesky J; Boffetta P; Lucas AL
Am J Gastroenterol; 2016 Sep; 111(9):1350-7. PubMed ID: 27430290
[TBL] [Abstract][Full Text] [Related]
11. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
12. 20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes:
Milano AF
J Insur Med; 2019; 48(1):5-23. PubMed ID: 31609640
[No Abstract] [Full Text] [Related]
13. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
14. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes for anaplastic pancreatic cancer: a population-based study.
Clark CJ; Graham RP; Arun JS; Harmsen WS; Reid-Lombardo KM
J Am Coll Surg; 2012 Nov; 215(5):627-34. PubMed ID: 23084492
[TBL] [Abstract][Full Text] [Related]
16. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data.
Li X; Liu Z; Ye Z; Gou S; Wang C
Pancreatology; 2018 Jan; 18(1):133-138. PubMed ID: 29170052
[TBL] [Abstract][Full Text] [Related]
17. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
Cronin KA; Lake AJ; Scott S; Sherman RL; Noone AM; Howlader N; Henley SJ; Anderson RN; Firth AU; Ma J; Kohler BA; Jemal A
Cancer; 2018 Jul; 124(13):2785-2800. PubMed ID: 29786848
[TBL] [Abstract][Full Text] [Related]
18. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
[TBL] [Abstract][Full Text] [Related]
19. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
